JY
LENZ

Jeff Yass’s LENZ Therapeutics LENZ Stock Holding History

Jeff Yass’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$191K Sell
33,700
-100,500
-75% -$810K ﹤0.01% 12001
2026
Q1 		$1.23M Buy
134,200
+11,400
+9% +$160K ﹤0.01% 7358
2025
Q4 		$1.96M Buy
122,800
+23,400
+24% +$682K ﹤0.01% 5695
2025
Q3 		$4.63M Buy
+99,400
New +$3.66M ﹤0.01% 4206
2024
Q1 		– Sell
-20,300
Closed -$372K – 13548
2023
Q4 		$372K Buy
+20,300
New +$335K ﹤0.01% 9358
2023
Q3 		– Sell
-16,329
Closed -$297K – 13162
2023
Q2 		$297K Sell
16,329
-428
-3% -$8.55K ﹤0.01% 9451
2023
Q1 		$287K Buy
+16,757
New +$271K ﹤0.01% 9819
2022
Q4 		– Sell
-3,357
Closed -$74K – 13879
2022
Q3 		$74K Sell
3,357
-357
-10% -$8.51K ﹤0.01% 11952
2022
Q2 		$72K Buy
+3,714
New +$82.8K ﹤0.01% 11746

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Jeff Yass's LENZ Position: Q2 2026 in Review

Jeff Yass sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 110,304 shares — an estimated $889K sold.

Jeff Yass first reported a position in LENZ in Q4 2022 and held it in 10 quarters. The position peaked at $2.35M in Q3 2025. 143 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Jeff Yass reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 110,304 LENZ Therapeutics shares in Q2 2026, an estimated $889K.
  • Jeff Yass first reported a position in LENZ Therapeutics in Q4 2022 and held it in 10 quarters.
  • Jeff Yass's LENZ Therapeutics position peaked at $2.35M in Q3 2025.
  • 143 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.